Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 8/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | ULK1 | O75385 | 2/20 | 0.42 |
| ▸ | IGF1R | P08069 | 2/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4921113 | 0.81 | CSF1R (0.51) | CSF1REGFRFGFR1LRRK2 | |
| SCHEMBL31590306 | 0.76 | PIK3CA (0.46) | CSF1REGFRSRCPTK2GAA | |
| SCHEMBL20355385 | 0.74 | EGFR (0.60) | EGFRSRC | |
| Hydrochloric Acid SCHEMBL28182076 | 0.74 | PDGFRB (0.58) | EGFRSYKUSP2LMNACYP1A2 | |
| Hydrochloric Acid SCHEMBL3757317 | 0.73 | EGFR (0.52) | CSF1REGFRIGF1R | |
| SCHEMBL7799235 | 0.72 | CSF1R (0.52) | CSF1REGFRFGFR1SYKULK1 | |
| SCHEMBL7800417 | 0.72 | LRRK2 (0.53) | CSF1REGFRFGFR1SRCIGF1R | |
| SCHEMBL1635586 | 0.71 | SYK (0.51) | EGFRFGFR1SRCSYKUSP2 | |
| SCHEMBL9911264 | 0.71 | LRRK2 (0.50) | EGFRSYKIGF1RLRRK2 | |
| SCHEMBL3568126 | 0.71 | EGFR (0.69) | EGFRFGFR1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050215574-A1 | 4-anilino quinazoline derivatives as antiproliferative agents | ASTRAZENECA AB (SE) | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215574-A1 | 4-anilino quinazoline derivatives as antiproliferative agents | ERBB2, ERBB4, EGFR | CSF1R 1097/4885EGFR 3/4885FGFR1 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.